M. Pittet

Immune monitoring in cancer immunotherapy.

D. Speiser, P. Romero, V. Cerundolo, 2000, Ernst Schering Research Foundation workshop.

Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376.

D. Speiser, P. Romero, V. Cerundolo, 1999, Cancer research.

Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide.

D. Speiser, P. Romero, D. Valmori, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Ex Vivo IFN-γ Secretion by Circulating CD8 T Lymphocytes: Implications of a Novel Approach for T Cell Monitoring in Infectious and Malignant Diseases1

D. Speiser, P. Romero, M. Pittet, 2001, The Journal of Immunology.

An antigen-targeted approach to adoptive transfer therapy of cancer.

P. Romero, V. Cerundolo, D. Valmori, 1999, Cancer research.

Optimum in vitro expansion of human antigen‐specific CD8+ T cells for adoptive transfer therapy

V. Appay, D. Speiser, P. Romero, 2005, Clinical and experimental immunology.

High frequency of functionally active Melan-A specific T cells in a patient with progressive immunoproteasome-deficient melanoma

B. Seliger, M. Rehli, A. Mackensen, 2004, Cancer Cell International.

Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.

D. Speiser, U. Şahin, P. Romero, 2000, Cancer research.

Addition of losartan to FOLFORINOX and chemoradiation downregulates pro-invasion and immunosuppression-associated genes in locally advanced pancreatic cancer

Jeffrey, Y. Boucher, M. Mino‐Kenudson, 2022, medRxiv.

The activatory receptor 2B4 is expressed in vivo by human CD8+ effector alpha beta T cells.

D. Speiser, P. Romero, M. Colonna, 2001, Journal of immunology.

Ex vivo analysis of tumor antigen specific CD8+ T cell responses using MHC/peptide tetramers in cancer patients.

D. Speiser, P. Romero, D. Valmori, 2001, International immunopharmacology.